title: Drug Insight: renal indications of calcimimetics.
abstract: Calcimimetics suppress the secretion of parathyroid hormone by sensitizing the parathyroid calcium receptor to serum calcium. Cinacalcet (Sensipar/Mimpara), Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is, in association with higher dose of a calcium-based oral phosphate binder, a well-tolerated and effective alternative to standard treatments such as vitamin D derivatives in association with a non-calcium-based oral phosphate binder. Here, we present an overview of evidence in support of this assertion. We extend our discussion to encompass other indications for calcimimetics -- secondary hyperparathyroidism in predialysis chronic kidney disease patients, hypercalcemic hyperparathyroidism in renal transplant recipients, primary hyperparathyroidism, and hypercalcemia associated with parathyroid carcinoma -- as well as providing guidance on optimal usage of this drug.
authors.affiliation: Department of Nephrology Internal Medicine, Amiens University Hospital, Jules Verne University of Picardy, France.
authors.forename: Irina
authors.initials: I
authors.lastname: Shahapuni
authors.forename: Matthieu
authors.initials: M
authors.lastname: Monge
authors.forename: Roxana
authors.initials: R
authors.lastname: Oprisiu
authors.forename: Hakim
authors.initials: H
authors.lastname: Mazouz
authors.forename: Pierre-François
authors.initials: PF
authors.lastname: Westeel
authors.forename: Philippe
authors.initials: P
authors.lastname: Morinière
authors.forename: Ziad
authors.initials: Z
authors.lastname: Massy
authors.forename: Gabriel
authors.initials: G
authors.lastname: Choukroun
authors.forename: Albert
authors.initials: A
authors.lastname: Fournier
mesh_terms: D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D016030:Kidney Transplantation; D009281:Naphthalenes / Q000494:pharmacology*; D010282:Parathyroid Neoplasms / Q000097:blood / Q000150:complications; D006435:Renal Dialysis
chemical_list: D009281:Naphthalenes; D002118:Calcium; D000069449:Cinacalcet